Dr. Lal Path Labs Ltd. — Investor Meet, 03-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs' Q3 FY26 revenue grew 10.6% YoY to ₹660 Cr, with EBITDA up 16.3% to ₹179 Cr (27.2% margin). PAT stood at ₹91 Cr, impacted by a one-time ₹30 Cr labor code cost. Patient volume growth was 2.7%, attributed to a decline in the seasonal fever portfolio, but Revenue Per Patient (RPP) increased 7.7% due to favorable test and geographic mix.

Management targets 11-12% organic revenue growth for FY26 and aims to maintain 27-28% EBITDA margins. Key initiatives include launching 'Sovaaka' for personalized preventive healthcare and expanding advanced radiology pilots. Swasthfit, contributing 26% to total revenue, continues scaling to Tier 2/3/4 towns. The company is actively exploring M&A opportunities, particularly in the South market. No price increases are expected for the next 2-3 quarters. The balance sheet remains robust with ₹1,411 Cr net cash.